Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRP-AM1977X Phase I QT/QTc Evaluation in Healthy Japanese Males
jRCT2080222958Phase 1Completed
- Sponsor
- Kyorin Pharmaceutical
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lascufloxacin in bacterial disease (4 arms), sponsored by Kyorin Pharmaceutical. Primary endpoint: Change in QTcF interval (double-delta QTcF). Started Sep 2015; status: completed.
02
Drugs
lascufloxacin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on jRCT2080222958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222958.